1. Home
  2. JBLU vs JANX Comparison

JBLU vs JANX Comparison

Compare JBLU & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JetBlue Airways Corporation

JBLU

JetBlue Airways Corporation

HOLD

Current Price

$5.06

Market Cap

1.5B

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$13.44

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBLU
JANX
Founded
1998
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
JBLU
JANX
Price
$5.06
$13.44
Analyst Decision
Sell
Strong Buy
Analyst Count
9
12
Target Price
$4.76
$60.27
AVG Volume (30 Days)
16.9M
2.3M
Earning Date
01-27-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,095,000,000.00
$10,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.34
$13.28
52 Week High
$8.31
$61.59

Technical Indicators

Market Signals
Indicator
JBLU
JANX
Relative Strength Index (RSI) 63.67 26.48
Support Level $4.51 $13.82
Resistance Level $4.70 $14.49
Average True Range (ATR) 0.19 0.47
MACD 0.00 0.36
Stochastic Oscillator 86.43 4.69

Price Performance

Historical Comparison
JBLU
JANX

About JBLU JetBlue Airways Corporation

JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: